Effects of olopatadine in limited scleroderma with peripheral eosinophils.
Scleroderma and eosinophilia often occur together, though the pathogenesis is unclear. We investigated the effect of olopatadine hydrochloride in a series of cases of limited scleroderma (LS). Ten patients with LS and positive eosinophil counts (LSE) were enrolled (average age, 85 years; six men and four women). Serum concentrations of the anti-Scl-70 antibody were positive. Olopatadine hydrochloride was prescribed at 10 mg/day for 3 weeks. Serum concentrations of the anti-Scl-70 antibody significantly decreased, but changes in eosinophil numbers and percentages in peripheral blood were not significant. Factor analysis suggested a correlation between serum concentrations of the anti-Scl-70 antibody and complement C4. Olopatadine could be effective in reducing anti-Scl-70 antibodies in the elderly with LSE.
Kikuchi
Motoo
M
Department of Medicine, Nanakuri Sanatorium, Fujita Health University, Tsu City, Japan. mtkikuchi-u@umin.ac.jp
Inagaki
Toshiaki
T
Hanaki
Hidekazu
H
Harada
Shinsuke
S
Ueda
Ryuzo
R
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000974:Antibodies, Antinuclear / Q000187:drug effects; D003181:Complement C4 / Q000187:drug effects; D003990:Dibenzoxepins / Q000008:administration & dosage / Q000627:therapeutic use*; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D000069605:Olopatadine Hydrochloride; D045745:Scleroderma, Limited / Q000097:blood / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D003181:Complement C4; D003990:Dibenzoxepins; D000069605:Olopatadine Hydrochloride; D007073:Immunoglobulin E